New
AVITA Medical: clinical trials in the USA
First patient enrolled in AVITA Therapeutic’s study in Miami earlier this week. The prospective study is evaluating the RECELL system for repigmentation of patients with stable vitiligo, meaning they have not had new vitiligo lesions or lesions that have expanded for at least one year.
AVITA’s technology creates an autologous suspension from a piece of the patient's own normal skin in under 30 minutes, to spray pigment-producing cells onto vitiligo lesion.
The company is about to begin two multi-center clinical trials in the USA (details 1 and details 2)
For more information, please contact: Elizabeth Kirshner at 661-367-9180 or ekirshner@avitamedical.com
FAQOther Questions
- Pyrostegia venusta as a folk medicine for vitiligo?
Pyrostegia venusta, also known as “flame vine” or “cipó-de-são-joão,” is a neotropical evergreen vine native to Brazil. It thrives in fields, coastal areas, forest edges, and ro...
- Red Wine and Vitiligo
Recent research has explored whether moderate red wine consumption might influence vitiligo risk, especially through genetic studies and large population data. What the Genetic ...
- PTSD in Vitiligo?
Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.